72
Participants
Start Date
July 31, 2009
Primary Completion Date
January 31, 2012
NK012
30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
Sarah Cannon Research Institute, Nashville
Lead Sponsor
Nippon Kayaku Co., Ltd.
INDUSTRY